• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶质载体家族25成员10(SLC25A10)在人类骨肉瘤中发挥致癌作用。

SLC25A10 performs an oncogenic role in human osteosarcoma.

作者信息

Wang Gaoyuan, Xia Jianjun, Chen Cheng, Qiu Jie, Sun Po, Peng Zhiwei, Chen Xiaoyu, Xu Bin

机构信息

Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China.

Department of Orthopaedics, East District of The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 231600, P.R. China.

出版信息

Oncol Lett. 2020 Oct;20(4):2. doi: 10.3892/ol.2020.11863. Epub 2020 Jul 14.

DOI:10.3892/ol.2020.11863
PMID:32774476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7405602/
Abstract

Osteosarcoma is one of the most common primary malignant bone tumors in adolescents. It is associated with high risk of relapse and the outcomes of patients with high-grade osteosarcoma remain poor. Therefore, additional studies investigating the molecular mechanisms involved in tumor initiation, growth, migration and invasion of osteosarcoma are necessary. In the present study, the protein levels of solute carrier family 25 member 10 (SLC25A10) were increased in osteosarcoma tissue, compared with normal bone tissue. In patients with osteosarcoma, high expression levels of SLC25A10 were associated with poor clinicopathological parameters, including metastasis, clinical Enneking stage, relapse-free survival and overall survival rates. Short hairpin RNA knockdown of SLC25A10 significantly suppressed cell proliferation as determined by cell counting, MTT assay and cell colony formation assays. In addition, SLC25A10 knockdown caused an increase in apoptosis and a decrease in mitosis in osteosarcoma cells. Cyclin E1 (CCNE1) was positively regulated by SLC25A10, while P21 and P27 were negatively regulated by SLC25A10. Therefore, SLC25A10 may play an oncogenic role in human osteosarcoma, which could be mediated by CCNE1, P21 and P27.

摘要

骨肉瘤是青少年最常见的原发性恶性骨肿瘤之一。它与高复发风险相关,高级别骨肉瘤患者的预后仍然很差。因此,有必要进行更多研究来探究骨肉瘤肿瘤起始、生长、迁移和侵袭所涉及的分子机制。在本研究中,与正常骨组织相比,骨肉瘤组织中溶质载体家族25成员10(SLC25A10)的蛋白水平升高。在骨肉瘤患者中,SLC25A10的高表达水平与不良临床病理参数相关,包括转移、临床Enneking分期、无复发生存率和总生存率。通过细胞计数、MTT试验和细胞集落形成试验确定,SLC25A10的短发夹RNA敲低显著抑制了细胞增殖。此外,SLC25A10敲低导致骨肉瘤细胞凋亡增加,有丝分裂减少。细胞周期蛋白E1(CCNE1)受SLC25A10正向调节,而P21和P27受SLC25A10负向调节。因此,SLC25A10可能在人类骨肉瘤中发挥致癌作用,这可能由CCNE1、P21和P27介导。

相似文献

1
SLC25A10 performs an oncogenic role in human osteosarcoma.溶质载体家族25成员10(SLC25A10)在人类骨肉瘤中发挥致癌作用。
Oncol Lett. 2020 Oct;20(4):2. doi: 10.3892/ol.2020.11863. Epub 2020 Jul 14.
2
Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo.敲低 lncRNA GHET1 抑制骨肉瘤细胞在体外和体内的增殖、侵袭、迁移和 EMT。
Cancer Biomark. 2018;23(4):589-601. doi: 10.3233/CBM-181863.
3
LncRNA-ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27.长链非编码RNA-ANCR通过与EZH2相互作用并影响p21和p27的表达来调节骨肉瘤细胞的生长。
J Orthop Surg Res. 2017 Jul 5;12(1):103. doi: 10.1186/s13018-017-0599-7.
4
The mitochondrial carrier SLC25A10 regulates cancer cell growth.线粒体载体SLC25A10调节癌细胞生长。
Oncotarget. 2015 Apr 20;6(11):9271-83. doi: 10.18632/oncotarget.3375.
5
Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways.S100A9的下调通过使丝裂原活化蛋白激酶(MAPK)和核因子κB(NF-κB)信号通路失活来抑制骨肉瘤细胞生长。
BMC Cancer. 2016 Mar 28;16:253. doi: 10.1186/s12885-016-2294-1.
6
MicroRNA-144 inhibits the proliferation, apoptosis, invasion, and migration of osteosarcoma cell line F5M2.微小RNA-144抑制骨肉瘤细胞系F5M2的增殖、凋亡、侵袭和迁移。
Tumour Biol. 2015 Sep;36(9):6949-58. doi: 10.1007/s13277-015-3396-0. Epub 2015 Apr 9.
7
Metformin downregulates the mitochondrial carrier SLC25A10 in a glucose dependent manner.二甲双胍以葡萄糖依赖的方式下调线粒体载体 SLC25A10。
Biochem Pharmacol. 2018 Oct;156:444-450. doi: 10.1016/j.bcp.2018.09.015. Epub 2018 Sep 15.
8
MiR-384 Inhibits Malignant Biological Behavior Such as Proliferation and Invasion of Osteosarcoma by Regulating IGFBP3.miR-384 通过调控 IGFBP3 抑制骨肉瘤的恶性生物学行为,如增殖和侵袭。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820909125. doi: 10.1177/1533033820909125.
9
Knockdown of Kinesin Family 15 Inhibits Osteosarcoma through Suppressing Cell Proliferation and Promoting Cell Apoptosis.敲低驱动蛋白家族 15 抑制骨肉瘤通过抑制细胞增殖和促进细胞凋亡。
Chemotherapy. 2019;64(4):187-196. doi: 10.1159/000505014. Epub 2020 Feb 19.
10
Knockdown of MSI1 inhibited the cell proliferation of human osteosarcoma cells by targeting p21 and p27.MSI1基因敲低通过靶向p21和p27抑制人骨肉瘤细胞的增殖。
Oncol Lett. 2017 Nov;14(5):5271-5278. doi: 10.3892/ol.2017.6870. Epub 2017 Sep 1.

引用本文的文献

1
Mitochondrial SLC25A10 promotes prostate cancer progression by inhibiting ferritinophagy.线粒体溶质载体家族25成员10通过抑制铁自噬促进前列腺癌进展。
Cell Death Discov. 2025 May 20;11(1):242. doi: 10.1038/s41420-025-02528-3.
2
RGS14 binds to GNAI3 and regulates the proliferation and apoptosis of human spermatogonial stem cells by affecting PLPP2 expression and MAPK signaling.RGS14与GNAI3结合,并通过影响PLPP2表达和MAPK信号传导来调节人类精原干细胞的增殖和凋亡。
Front Cell Dev Biol. 2025 Apr 25;13:1593595. doi: 10.3389/fcell.2025.1593595. eCollection 2025.
3
The Role of Mitochondrial Solute Carriers SLC25 in Cancer Metabolic Reprogramming: Current Insights and Future Perspectives.

本文引用的文献

1
Sirtuin 2 expression suppresses oxidative stress and senescence of nucleus pulposus cells through inhibition of the p53/p21 pathway.Sirtuin 2 的表达通过抑制 p53/p21 通路抑制核髓核细胞的氧化应激和衰老。
Biochem Biophys Res Commun. 2019 Jun 4;513(3):616-622. doi: 10.1016/j.bbrc.2019.03.200. Epub 2019 Apr 10.
2
MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer.微小 RNA-107 通过直接靶向卵巢癌细胞周期蛋白 E1 诱导细胞周期停滞。
Biochem Biophys Res Commun. 2019 Apr 30;512(2):331-337. doi: 10.1016/j.bbrc.2019.03.009. Epub 2019 Mar 16.
3
CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
线粒体溶质载体SLC25在癌症代谢重编程中的作用:当前见解与未来展望
Int J Mol Sci. 2024 Dec 26;26(1):92. doi: 10.3390/ijms26010092.
4
Targeting Mitochondrial Metabolic Reprogramming as a Potential Approach for Cancer Therapy.靶向线粒体代谢重编程作为一种潜在的癌症治疗方法。
Int J Mol Sci. 2023 Mar 4;24(5):4954. doi: 10.3390/ijms24054954.
5
Identification and validation of a gene-based signature reveals SLC25A10 as a novel prognostic indicator for patients with ovarian cancer.鉴定和验证一个基于基因的标志物,揭示 SLC25A10 是卵巢癌患者的一个新的预后指标。
J Ovarian Res. 2022 Sep 16;15(1):106. doi: 10.1186/s13048-022-01039-4.
6
Identification of a Solute Carrier Family-Based Signature for Predicting Overall Survival in Osteosarcoma.基于溶质载体家族特征预测骨肉瘤总生存期的研究
Front Genet. 2022 Apr 19;13:849789. doi: 10.3389/fgene.2022.849789. eCollection 2022.
7
An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis.对结肠癌中线粒体溶质载体家族 25(SLC25)的综合生物信息学研究,随后对成员 5(SLC25A5)在肿瘤发生中的初步验证。
Cell Death Dis. 2022 Mar 14;13(3):237. doi: 10.1038/s41419-022-04692-1.
8
In Sickness and in Health: The Oxygen Reactive Species and the Bone.患难与健康:氧活性物质与骨骼
Front Bioeng Biotechnol. 2021 Nov 23;9:745911. doi: 10.3389/fbioe.2021.745911. eCollection 2021.
CCNE1 扩增与三阴性乳腺癌患者的预后不良相关。
BMC Cancer. 2019 Jan 21;19(1):96. doi: 10.1186/s12885-019-5290-4.
4
miR-29 promotes osteosarcoma cell proliferation and migration by targeting PTEN.微小RNA-29通过靶向磷酸酶和张力蛋白同源物促进骨肉瘤细胞增殖和迁移。
Oncol Lett. 2019 Jan;17(1):883-890. doi: 10.3892/ol.2018.9646. Epub 2018 Oct 31.
5
MORF4L1 suppresses cell proliferation, migration and invasion by increasing p21 and E-cadherin expression in nasopharyngeal carcinoma.MORF4L1通过增加鼻咽癌中p21和E-钙黏蛋白的表达来抑制细胞增殖、迁移和侵袭。
Oncol Lett. 2019 Jan;17(1):294-302. doi: 10.3892/ol.2018.9588. Epub 2018 Oct 16.
6
ARHGAP17 suppresses tumor progression and up-regulates P21 and P27 expression via inhibiting PI3K/AKT signaling pathway in cervical cancer.ARHGAP17 通过抑制 PI3K/AKT 信号通路抑制宫颈癌的肿瘤进展并上调 P21 和 P27 的表达。
Gene. 2019 Apr 15;692:9-16. doi: 10.1016/j.gene.2019.01.004. Epub 2019 Jan 11.
7
Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.长链非编码 RNA UCA1 通过调节 EZH2/p21 轴和 PI3K/AKT 信号通路赋予乳腺癌内分泌治疗中他莫昔芬耐药性。
Int J Oncol. 2019 Mar;54(3):1033-1042. doi: 10.3892/ijo.2019.4679. Epub 2019 Jan 8.
8
Long non-coding RNA DANCR promotes the progression of non-small-cell lung cancer by inhibiting p21 expression.长链非编码RNA DANCR通过抑制p21表达促进非小细胞肺癌进展。
Onco Targets Ther. 2018 Dec 21;12:135-146. doi: 10.2147/OTT.S186607. eCollection 2019.
9
MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 PAX3.微小RNA-1通过上调p21和PAX3抑制骨肉瘤细胞增殖。
Cancer Genomics Proteomics. 2019 Jan-Feb;16(1):71-79. doi: 10.21873/cgp.20113.
10
MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis, migration, and invasion by targeting CDKN1B/p27.MicroRNA-221 通过靶向 CDKN1B/p27 调节骨肉瘤细胞的增殖、凋亡、迁移和侵袭。
J Cell Biochem. 2019 Mar;120(3):4665-4674. doi: 10.1002/jcb.27755. Epub 2018 Dec 23.